C4 Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo

Wells Fargo analyst Derek Archila upgraded C4 Therapeutics (CCCC) to Overweight from Equal Weight with a price target of $12, up from $8. The shares “are cheap” and Wells is now more confident in cemsidomide’s efficacy and safety profile and potential for future combinations, the analyst tells investors in a research note. The firm expects a partnership for the asset and thinks updates on CFT1946 in 2025 “should offer upside.” Cemsidomide’s early profile looks differentiated, the analyst tells investors in a research note.